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Abstract 
Background: Cardiovascular disease (CVD) is among the most common causes of mortality in all populations. Nonalcoholic steatohepa-
WLWLVLVDFRPPRQ¿QGLQJLQSDWLHQWVZLWK&9'3UHYHQWLRQRI&9'LQLQGLYLGXDOSDWLHQWVW\SLFDOO\UHTXLUHVSHULRGLFFOLQLFDOHYDOXDWLRQDVZHOO 
as diagnosis and management of risk factors such as hypertension and hyperlipidemia. However, this is resource consuming and hard to 
LPSOHPHQWHVSHFLDOO\LQGHYHORSLQJFRXQWULHV:HGHVLJQHGDVWXG\WRLQYHVWLJDWHWKHHIIHFWVRIDVLPSOHUVWUDWHJ\D¿[HGGRVHFRPELQD-
WLRQSLOOFRQVLVWLQJRIDVSLULQYDOVDUWDQDWRUYDVWDWLQDQGK\GURFKORUWKLD]LGH3RO\3LOOLQDQXQVHOHFWHGJURXSRISHUVRQVDJHGRYHU\HDUV 
Design:7KH3RO\,UDQ/LYHUVWXG\ZDVSHUIRUPHGLQ*RQEDGFLW\DVDQRSHQODEHOSUDJPDWLFUDQGRPL]HGFRQWUROOHGWULDOQHVWHGZLWKLQ 
WKH*ROHVWDQ&RKRUW6WXG\:HUDQGRPO\VHOHFWHGFRKRUWVWXG\SDUWLFLSDQWVDJHGDERYH\HDUVUDQGRPO\DVVLJQHGWKHPWRLQ-
tervention or usual care and invited them to participate in an additional measurement study (if they met the eligibility criteria) to measure 
OLYHUUHODWHGRXWFRPHV7KRVHDJUHHLQJDQGUDQGRPL]HGWRWKHLQWHUYHQWLRQDUPZHUHRIIHUHGDGDLO\VLQJOHGRVHRI3RO\3LOO:HZLOOIROORZ 
SDUWLFLSDQWVIRU\HDUV7KHSULPDU\RXWFRPHLVPDMRUFDUGLRYDVFXODUHYHQWVVHFRQGDU\RXWFRPHVLQFOXGHDOOFDXVHPRUWDOLW\DQGOLYHU 
related outcomes: liver stiffness and liver enzyme levels. Cardiovascular outcomes and mortality will be determined from the cohort study 
and liver-related outcomes in those consenting to follow up. Analysis will be by allocated group. 
Trial status:%HWZHHQ2FWREHUDQG'HFHPEHULQWHUYHQWLRQDQGFRQWUROSDUWLFLSDQWVZHUHLQYLWHGWRSDUWLFLSDWHLQWKH 
additional measurement study. For all these participants, the major cardiovascular events will be determined using blind assessment of 
RXWFRPHVWKURXJKWKHFRKRUWVWXG\,QWKHLQWHUYHQWLRQDQGFRQWURODUPVDQGUHVSHFWLYHO\PHWWKHHOLJLELOLW\FULWHULD 
and agreed to participate in the additional measurement study. Liver related outcomes will be measured in these participants. Of the 1,320 
SDUWLFLSDQWVUDQGRPL]HGWRWKHLQWHUYHQWLRQDFFHSWHGWKH3RO\3LOO 
Conclusion:7KH3RO\,UDQOLYHUXUEDQVWXG\ZLOOSURYLGHXVZLWKLPSRUWDQWLQIRUPDWLRQRQWKHHIIHFWLYHQHVVRI3RO\3LOORQPDMRUFDUGLRYDV-
FXODUHYHQWVDOOFDXVHPRUWDOLW\DQGOLYHUUHODWHGRXWFRPHV&OLQLFDO7ULDOVJRY,'1&7 
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Introduction 
As control and characterization of infectious diseases im­prove in the developing world, non-communicable dis­
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eases (NCD), particularly cardiovascular diseases (CVD), be­
come more important. In Iran, cardiovascular disease (CVD)
causes over 50% of non-communicable disease mortality in mid­
dle and old age.1 Nonalcoholic fatty liver disease is currently the
most common liver disease in Iran and the majority of subjects
with the condition will die of CVD.
The current approach to clinical prevention of CVD is to iden­
tify patients with elevated risk factors through regular clinic visits
and periodic clinical assessment and to offer treatment. However,
the seemingly simple task of periodic clinical assessment requires
substantial clinical resources and is not always an option in de­
veloping countries. Furthermore, it is not always easy to achieve
patient and physician commitment which is required for this type
of prevention. 
One alternative which has recently gained major attention is pro­
YLGLQJLQGLYLGXDOVZLWKD¿[HGGRVHGFRPELQDWLRQSLOOUHJDUGOHVV 
of the presence of current risk-factors.2 This eliminates the need
IRUSHULRGLFDVVHVVPHQWDQGJUHDWO\VLPSOL¿HVWKHWUHDWPHQW 
There is good evidence that for primary and secondary preven-
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tion of CVD, aspirin reduces the incidence of CVD and statins
reduce both incidence and mortality from CVD.3–6 Reducing el­
evated blood pressure using antihypertensive agents such as di­
uretics, angiotensin enzyme inhibitors and angiotensin receptor
EORFNHUVFDQEHDOVREHQH¿FLDOLQUHGXFLQJ&9'ULVN7 
Nonalcoholic fatty liver disease (NAFLD) and the more severe
non-alcoholic steatohepatitis (NASH) are also common in popu­
lations at high risk of CVD.8–10 Mechanisms have already been
suggested for the causal relationships between NASH and ath­
erosclerosis.11 Thus, preventive cardiovascular measures, such as
PolyPill, might be more effective in participants with NASH or
NAFLD than in the general population and might also have ben­
H¿FLDOHIIHFWVRQOLYHUGLVHDVH12–15 
:HKDYHDOUHDG\FRQGXFWHGDSLORWVWXG\RID¿[HGGRVHFRPEL­
nation pill (PolyPill) containing aspirin, atorvastatin, hydrochlor­
thiazide and enalapril in the general population.16 We are also
studying the long term effects of this combination (or valsartan
if participants are intolerant of enalapril) in a cluster randomized
controlled trial in a rural population.17 In the present study, we will
HYDOXDWH WKHHIIHFWRI WKLV¿[HGGRVHFRPELQDWLRQSLOORQPDMRU 
cardiovascular events, mortality and liver outcomes in a pragmat­
ic individually randomized controlled trial in an urban population.
We will also investigate the effects of the PolyPill on CVD and
liver outcomes in a subgroup of patients with presumed NASH
(pNASH) or NAFLD (pNAFLD) at baseline. 
Materials and Methods 
The PolyIran-Liver study is designed as an open-label, pragmat­
ic, parallel individually randomized controlled trial with a 110:90
allocation ratio (PolyPill: Control). It is nested in the Golestan Co­
hort Study.187KHDLPLVWRVWXG\WKHHIIHFWVRID¿[HGGRVHFRP­
bination pill (PolyPill) comprising aspirin, atorvastatin, hydro­
chlorothiazide and valsartan on CVD and liver-related outcomes
linked to non-alcoholic fatty liver disease.
Trial design 
This randomized controlled trial is nested within the Golestan
FRKRUWVWXG\DQGFRQVLVWVRIWZRSDUWV7KH¿UVWLVD=HOHQGHVLJQ19 
and includes all randomly selected participants with outcomes as­
sessed through the cohort study. The second is an additional mea­
surement study investigating liver related outcomes in those who
agree to liver related measurements and meet the eligibility crite­
ria. Those in the intervention arm are offered a PolyPill if agreeing
to participate in the additional measurement study and meeting
the eligibility criteria. 
Participants 
The Golestan Cohort Study was originally designed to study
upper gastrointestinal cancers and includes 50,045 healthy par­
ticipants who are being followed up for major health outcomes,
including cardio-vascular outcomes.18 There are few exclusion
criteria for the Golestan Cohort Study; participants are perma­
nently resident in Golestan province, aged 40 to 70 years, without
a previous diagnosis of upper gastrointestinal cancer. Participants
were eligible for the Zelen design trial if they were a member of
the cohort study participants, older than 50 years and resident in
Gonbad city. A random sample of eligible participants from the
cohort study was selected for the Zelen trial. Participants were
eligible for the additional measurement study if they met further
eligibility criteria and agreed to participate. The eligibility criteria
included no recent upper gastro-intestinal bleeding, hypotension
or important morbidities (e.g., debilitating psychological illness)
and the ability to make an informed treatment decision (Table 1).
Intervention 
The intervention (PolyPill) is a combination pill including 80
mg aspirin, 12.5 mg hydrochlorthiazide, 20 mg atorvastatin and
40 mg valsartan (PolyPill 4–2, Alborz-Darou, Ghazvin, Iran), tak­
en once a day. The timing of the dose was at participants’ discre­
tion although we recommended taking the dose at bedtime.
Each participant was given a single PolyPill and asked to return
Table 1. Criteria making participants ineligible for the additional measurement study. 
Proven moderate or severe asthma 
Rhinitis 
Nasal polyp 
Tinnitus or hearing loss 
Bleeding diathesis such as hemophilia 
Using anticoagulants 
Hepatitis B or C 
Anemia (Hemoglobin levels less than 10g/dL for women and less than 11g/dL for men) 
Renal failure (Creatinine over 2mg/dL or GFR < 30 mL/min) 
Upper GI bleeding in the recent 3 months 
Clinical cirrhosis or active hepatitis 
Pregnancy or willing to become pregnant in the next 5 years 
Lactation 
Uncontrolled convulsion 
Uric acid greater than 7 mg/dL for women and greater than 8.5 mg/dL for men 
Angioedema 
Hypotension (systole less than 90mmHg or diastole less than 60mmHg in at least two separate measurements) 
Debilitating psychological illness 
Physical disability hindering mobility and ability to cooperate 
Other severe debilitating conditions 
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the next day for a brief examination. Participants returning the
next day without any immediate adverse drug reactions continued
to receive the PolyPill. Those not returning were contacted and
the reason recorded. These participants were regarded as having
discontinued treatment or withdrawn consent accordingly.
Participants who were already taking aspirin, a statin or a low-
dose diuretic had it discontinued and replaced by the PolyPill. If
other antihypertensive medications were being taken, they were
either discontinued or the dose was adjusted by the study phy­
sician. All participants for whom antihypertensive medications
ZHUHPRGL¿HGZHUHDOVRDGYLVHGWRFRQVXOWWKHLURZQGRFWRUZLWK­
in the following week in case further adjustments were required. 
Eligible participants were provided with a supply of PolyPill and
asked to return for two additional visits at months one and two to
check for important adverse drug reactions.
Control 
Participants allocated to the control arm received no interven­
tion and were followed up as explained below. The usual medical
practice in Gonbad is that people refer to their doctor only if they
have symptoms or if they wish to undergo medical examination.
Regular check-ups are not performed unless asked for. 
Baseline characteristics 
In the Zelen trial, baseline measurements are not available for all
randomized participants because only those included in the addi­
tional measurement study underwent baseline assessment.
In the additional measurement study, baseline assessments in­
cluding height, weight, waist and hip circumference and blood
pressure are measured along with additional blood and liver re­
lated measurements. In brief, 10cc blood was drawn for labora­
tory tests including liver enzymes, lipid levels, renal function,
complete blood count, measures of glycemia, insulin and insulin
resistance. Ultrasonography and Doppler examination were per­
formed as explained below. Liver stiffness was measured using
the FibroScan machine (Echosens, Paris, France) using the M or
XL probes as appropriate. 
8OWUDVRXQGDVVHVVPHQWVZHUHSHUIRUPHGXVLQJDQ$FFXYL[;4 
ultrasound unit (Medison, Seoul, Korea) equipped with a 3–7
MHz curved-array and a 5–12 MHz linear-array transducer for
evaluation of liver, abdominal fat and carotid arteries. Presence
of fatty liver was determined using the ultrasonographic scoring
V\VWHPZKLFKSURYLGHVKLJKVHQVLWLYLW\DQGVSHFL¿FLW\ 
(100%) for the histological diagnosis of fatty liver.20 Ultrasono­
JUDSKLF¿QGLQJVVFRUHGLQWKLVSURWRFROLQFOXGHGKHSDWRUHQDOHFKR 
contrast and/or liver brightness (0 to 3), deep attenuation (0 to 2),
and vascular blurring (0 to 1). The fatty liver diagnosis (pNAFLD)
requires a total score of at least 2, which includes the hepatorenal
echo contrast and/or bright liver score of at least 1. The severity
RIVWHDWRVLVLVFODVVL¿HGDFFRUGLQJWRWKHWRWDOIDWW\OLYHUVFRUHDV 
0 to 1 (no fatty liver), 2 to 3 (mild fatty liver), or 4 to 6 (moderate
to severe fatty liver).21 
Measurement of Visceral Adipose Tissue thickness (VAT) and
Subcutaneous Adipose Tissue thickness (SAT) used previously
described techniques.21,229$7PPZDVGH¿QHGDVWKHGLVWDQFH 
between the anterior wall of the aorta and the internal face of the
rectus abdominis muscle perpendicular to the aorta, which has
been shown to have strong correlations with visceral fat area mea­
sured by computed tomography.23 SAT (mm) was determined as
the thickness of the fat tissue between the skin-fat interface and
the linea alba, perpendicular to the skin, avoiding any compres­
sion. Ultrasonographic assessment of SAT has been described as
a valid and reliable technique.24 VAT and SAT measurements were
obtained 1 cm above the umbilicus. Participants were assessed in
the supine position following at least 6 hours of fasting. 
The common and internal carotid arteries on both sides were
also evaluated. Participants were examined in the supine position
with the neck extended and the head turned 45° to the right or left.
Carotid Intima-Media Thickness (mm) (IMT) was determined as
the distance between the lumen–intima interface and the media– 
adventitia interface, measured at its thickest point on the distal
(far) wall of the common carotid arteries, 1.5–2 cm proximal to
the carotid bulb. The average of right and left sides was consid­
ered as common carotid artery IMT.25 A localized thickening of
>1.2 mm in common and internal carotid arteries, not involving
WKHZKROHFLUFXPIHUHQFHRIWKHOXPHQZDVGH¿QHGDVDWKHURVFOH­
rotic plaque.26 
Liver stiffness was measured by transient elastography using the
FibroScan® 502 (EchoSense, Paris, France, 5MHz). According
to the manufacturer’s guidelines, the M probe was used for par­
ticipants with a thoracic perimeter less than 110 cm and the XL
probe for 110 cm and above. With the patient lying in the dorsal
decubitus position with maximal abduction of the right arm, the
probe was placed on the patient’s skin, overlying the right lobe of
the liver, through the intercostal spaces. At least 10 measurements
were done for each patient and the median value was recorded.
9DOXHVZHUHFRQVLGHUHGYDOLGLIWKHLQWHUTXDUWLOHUDQJH,45ZDV 
less than 30% of the median reading and the success rate was at
least 60%. 
A single experienced radiologist performed ultrasound examina­
tions without knowledge of participants’ demographic and clini­
cal data but was not blinded to the participants’ allocation status.
The examiner, when performing carotid assessment in a separate
session, was also not blinded to the allocation status but was un­
DZDUHRIOLYHUDQGDEGRPLQDOIDWXOWUDVRXQG¿QGLQJV 
Outcomes 
The primary outcome is the occurrence of a major cardiovascu­
ODUHYHQWGH¿QHGDVKRVSLWDOL]DWLRQIRUDFXWHFRURQDU\V\QGURPH 
(non-fatal myocardial infarction and unstable angina), fatal myo­
cardial infarction, sudden death, new-onset heart failure, coronary
artery revascularization procedures and stroke (fatal or non-fatal).
Secondary outcomes include all-cause mortality and the indi­
vidual components of the primary outcome and also liver related
secondary outcomes: changes in liver stiffness, liver enzyme lev­
els, Visceral Adipose Tissue thickness (VAT), Subcutaneous Adi­
pose Tissue thickness (SAT) and carotid Intima-media thickness
(IMT). Additional secondary outcomes include the proportion of
patients with pNASH and pNAFLD. Compliance and adverse
events will also be assessed. 
Measurement of outcomes 
Outcomes will be assessed at 2.5 and 5 years of follow up, with
RXWFRPHDW¿YH\HDUVEHLQJWKHSULPDU\HQGSRLQW3ULPDU\DQG 
secondary cardiovascular outcomes and all-cause mortality are
independently determined by routine annual follow up as part of
the Golestan cohort study. Therefore, cardiovascular outcomes
will be available for all randomized participants irrespective of
whether they participated in the additional measurement study.
,Q WKH *ROHVWDQ FRKRUW VWXG\ PRUWDOLW\ DQG VLJQL¿FDQW PHGLFDO 
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events are recorded in detail by investigating all available medical
records. The cohort study follow up team is blind to the allocation
status of participants in this trial.
In participants included in the additional measurement study,
liver related secondary outcomes will be assessed as described
above.
6DPSOHVL]HMXVWL¿FDWLRQ 
The sample size includes 1,320 in the intervention arm and 1,080
in the control arm. For the primary outcome, the expected follow-
up through the cohort study is around 80% over 5 years. The ex­
pected cumulative incidence in the control arm over 5 years is
anticipated to be in the region of 0.0826 (=1-(1-0.0171)5) where
0.0171 is the yearly per-person incidence of major cardiovascular
HYHQWVLQWKHFRKRUWVWXG\XQSXEOLVKHGGDWDDQGZHFRXQW¿UVW 
HYHQWVRQO\$FOLQLFDOO\LPSRUWDQWHIIHFWVL]HZDVSUHVSHFL¿HGWR 
be in the region of 0.60 (relative risk scale). Assuming therefore
that outcome data are available on 1,920 individuals, this trial is
in the region of 80% power (assuming a chi-squared test for pro­
portions with continuity correction). This power calculation was
carried out in Stata 13 using the power function.
We are not powered to detect differences in subgroup analyses
but based on our experience in this population, we anticipated a
25% prevalence of increased liver enzymes, which is one of our
GH¿QLWLRQVIRUS1$6+27,28 
Randomization 
The Golestan cohort study includes 7,351 participants aged older
than 50 years and living in Gonbad. From these, 2,400 were ran­
domly selected of which 1200 were males and 1200 were females.
This was to achieve a 50/50 sex ratio. The 2,400 participants thus
selected were randomized into two arms; PolyPill (intervention)
group and control group. We chose to randomize into PolyPill and
control arms with a 110:90 ratio, using unrestricted randomiza­
WLRQ ZLWKRXW EORFNLQJ RU VWUDWL¿FDWLRQ 7KH UDQGRPL]DWLRQ ZDV 
performed by a statistician from the Digestive Disease Research
Institute of Tehran University of Medical Sciences independent
from the study group. 
Invitation and enrollment 
Following randomization, the participants were contacted by
telephone by the Golestan cohort invitation team which was blind
to the allocation status of participants. Participants were asked
if they would be willing to take part in an additional measure­
ment study. They were informed that this would consist of ad­
ditional laboratory tests, ultrasonography and liver stiffness mea­
surements. Participants randomized to the intervention arm were
informed about the trial after baseline measurements were made
and then offered the PolyPill.
At the time when the patients were asked to participate, their al­
location was known, as is the case in a Zelen design.19 However,
all participants allocated to the PolyPill and control arms will be
followed up within the cohort study for the primary outcome,
all-cause mortality and the individual components of the primary
outcome. Therefore, from the perspective of an intention to treat
analysis of these outcomes, allocation was concealed. Liver-re­
lated outcomes were assessed only in those participants who met
the eligibility criteria and consented to the additional measure­
ment study and therefore allocation was not concealed for these
outcomes.
Blinding 
Because this is a pragmatic trial, participants are not blind to
their treatment status. However, outcome assessment for the pri­
mary outcome (major cardiovascular events), all-cause mortality
and the individual components of the primary outcome will be
blind to allocation. Liver outcomes will also be assessed blind to
allocation status. 
Follow up 
All selected participants are followed up through the Golestan
Cohort Study to which they had previously consented. Partici­
pants who consented to the additional measurement study are also
followed up every 6 months for 5 years. On each follow up visit,
a short questionnaire is completed; weight, waist circumference,
and hip circumference are measured; blood pressure is measured
and the participant is advised to visit their doctor if the systolic
blood pressure is found to be greater than 140 mmHg or the dia­
stolic greater than 90 mmHg. The questionnaire includes adverse
events, additional medicines used by the participant and events
leading to medical attention since the last follow-up. 
Analysis plan 
For participants selected from the cohort study and randomly
allocated to the PolyPill or control, cohort characteristics from
WKHLUGDWHRIFRKRUWVWXG\HQUROOPHQWZLOOEHFRPSDUHGWRFRQ¿UP 
that allocation was random. Additionally, the baseline character­
istics of those enrolled in the additional measurements study will
be summarized. These characteristics will be summarized using
appropriate summary statistics: numbers and percentages for cat­
egorical variables; means and standard deviations or medians and
interquartile ranges for continuous variables.
Analyses of primary outcome and the secondary cardiovascular
outcomes will be by intention to treat: all participants for whom
outcomes are available will be analyzed in the arm to which they
were allocated. The primary aim of the study is to evaluate wheth­
er there is a difference in the proportion of people in intervention
and control arms experiencing these outcomes. As these outcomes
are binary, we will report the risks of the events in both arms, the
relative risks and also report the risk differences along with their
FRQ¿GHQFHLQWHUYDOV7HVWVRIVWDWLVWLFDOVLJQL¿FDQFHZLOOEH 
performed using Fisher’s exact test. This analysis will be unad­
justed because we do not have baseline covariates on all of the
participants allocated to the intervention and control arms. 
Secondary liver-related outcomes will be analyzed only in par­
ticipants included in the additional measurement study. All par­
ticipants for whom outcomes are available will be analyzed in
the arm to which they were allocated, but it is recognized that
outcomes will not be available for a large proportion of partici­
pants. Secondary liver-related outcomes will be analyzed in two
GLIIHUHQWZD\VWKH¿UVWDQDO\VLVLVRQO\DGMXVWHGIRUEDVHOLQHYDO­
ues of that outcome and the second analysis additionally adjusted
IRUEDVHOLQHYDOXHVRIDSUHVSHFL¿HGVHWRIFOLQLFDOO\LPSRUWDQW 
covariates. The covariates to be included in the adjustment will be
SUHVSHFL¿HGDQGZLOOLQFOXGHDJHVH[GLDEHWLFVWDWXVDQGSUHYL­
ous history of cardiovascular disease. For the secondary analysis,
adjusting for covariates, we will use the generalized linear model
with an appropriate transformation to accommodate non-normal­
ity to obtain an adjusted estimate of the treatment effect. We do
not anticipate any missing baseline covariate data; therefore, no
missing data methods will be needed. Secondary binary outcomes
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will be analyzed with adjustment for baseline presence of that
RXWFRPH)RUFRQWLQXRXVRXWFRPHVZHZLOO¿WDQDSSURSULDWHO\ 
transformed generalized linear model and report mean differenc­
HV)RUELQDU\ RXWFRPHVZHZLOO ¿W3RLVVRQUHJUHVVLRQPRGHOV 
with robust standard errors and report relative risks and risk dif­
ferences. 
Finally, to explore the effect of the treatment in those who ad­
hered to the study medication, we will also estimate the complier
average causal effect.29 The instrument used in this will be either
whether or not the patient accepted the Polypill or another mea­
surement of compliance using the data assessed through the pill-
counts.
Interim analyses will occur after 2.5 years for review by the
monitoring committee. Interim analyses may provide an oppor­
WXQLW\WRH[DPLQHDQGFRQ¿UPRUDGDSWWKHDVVXPSWLRQVXVHGLQ 
sample size estimation. Formal statistical methods will be used as
guidelines rather than absolute rules. Differences between major
endpoints of at least equivalent to P < 0.001 (similar to Haybittle-
Peto boundary) will be considered the order of magnitude neces­
VDU\WRFRQVLGHUDQ\VWXG\PRGL¿FDWLRQRUVWRSSLQJWKHWULDO30 
Subgroups 
Ideally, to evaluate the effect of the PolyPill on cardiovascular
outcomes in participants with NASH, we will identify the sub­
set of patients with fatty liver disease at baseline. However, both
NASH and NAFLD can only be diagnosed by liver biopsy which
is invasive and carries risks.31:HWKHUHIRUHLGHQWL¿HGWKUHHVXE­
groups for secondary analysis of outcomes: pNAFLD, diagnosed
E\XOWUDVRQRJUDSK\DVH[SODLQHGDERYHS1$6+GH¿QHGDVS1­
AFLD and any elevation of alanine transaminase (ALT) levels
above the upper limit of normal (30 and 20 IU/L for men and
women, respectively); and elevated ALT levels only. In each case,
the participant should not have a diagnosis of hepatitis B or C.
$OWKRXJKWKHUHLVQRFRQVHQVXVRQWKLVGH¿QLWLRQZHEHOLHYHLWLV 
the closest approximation that can be made in a population-based
study.32,33 Further subgroup analyses will investigate outcomes by
sex and by BMI category normal weight (<25 kg/m2), overweight
(25 to 29.9 kg/m2DQGREHVHNJP2). 
Ethics 
The study protocol was approved by the institutional review
board of the Digestive Diseases Research Institute of Tehran
University of Medical Sciences and ethics committees at Tehran
University of Medical Science and Ministry of Health and Medi­
cal Education. Written informed consent was obtained from all
participants and it was explained that they will be free to leave the
study at any time. The protocol is registered at ClinicalTrials.gov,
ID: NCT01245608. 
Important changes after trial commencement 
Initially this trial was intended to investigate the effects of a
PolyPill on liver related outcomes in participants with pNASH
selected from the Golestan Cohort Study. The original design was
therefore the additional measurement study with liver related out­
comes as the primary outcomes. However, this design suffered
from lack of allocation concealment and a risk of selection bias
and imbalance between the intervention and control arms. We
therefore changed the primary outcome to major cardiovascular
events which could be ascertained for all randomized participants
through the Golestan Cohort Study.
All patients in the Golestan Cohort Study have previously given
consent to be followed up for cardiovascular and other major dis­
ease outcomes; therefore, their previous consent includes follow
up for the changed primary outcome and the wider group in which
outcomes are to be assessed. We sought and received ethical com­
PLWWHHDSSURYDOWRFRQ¿UPWKLV 
Results 
7KHÀRZRISDUWLFLSDQWVLVVKRZQLQ)LJXUH7KHUHZHUH 
participants selected from Golestan cohort study for participation
in this study: 1320 participants were randomized to the interven­
tion arm and 1080 to the control arm. Of these, 21 participants
(13 intervention, 8 control) had moved and 113 (58 intervention,
55 control) had died before they could be invited to participate in
this study (Table 2). These participants will not be included in the
Zelen trial. Cohort characteristics from their date of cohort study
enrollment (2004–2008) are available for the remaining 1249 in­
tervention and 1017 control participants in the Zelen trial. The
mean age of participants in 2011 was 59.8 years and 49.7% were
male. Socio-economic, demographic and measurement character­
istics of the Zelen intervention and control trial groups were very
similar at their date of cohort study enrollment (Table 3). 
After invitation by telephone, an additional 218 in the interven­
tion arm and 186 in the control arm refused to participate in the
additional measurement study, could not attend, could not be con­
tacted or failed to attend for baseline assessment (Table 2). For
these 538 participants (289 plus 249) no baseline measurements
were taken. This left 1031 participants in the intervention group
and 831 in the control group who attended baseline assessment
for the additional measurements study. Baseline history, physi­
cal examination and laboratory were undertaken for these 1862
participants. Liver stiffness measurement, ultrasonography and
Doppler examination were also performed as explained above.
6RPH RI WKH EDVHOLQH XOWUDVRQRJUDSK\ ¿QGLQJV KDYH EHHQ SXE­
lished separately.34 The mean age of participants in the additional
measurement study was 58.9 years and 51.2% were male. The
intervention and control groups had similar height, weight, hip
circumference, waist circumference and measures of livers stiff­
ness. Participants in the intervention group had higher lipid levels
than the control group (total cholesterol 218.5 and 206.9 mg/dL,
respectively) and lower mean blood pressures (130.8/78.2 and
135/82.4 mm Hg, respectively) (Table 4). 
Following baseline measurements, 156 participants in the inter­
vention group and 110 in the control group were found to have
contraindications to the PolyPill. The most common contraindica­
tions are given in Table 5. A further 88 participants in the inter­
vention group did not complete the run in period. This left 787
(59.6%) of those randomized to PolyPill and 721 (66.8%) of those
allocated to control to be included in the additional measurements
study.
Discussion 
This study design selects patients from within an existing cohort
study for inclusion in a randomized controlled trial in order to de­
termine whether use of PolyPill in largely unselected population
has an effect on cardiovascular outcomes. The study has a Zelen
design because participants randomized to the control group have
already consented to follow up within the cohort study. A subset
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3RO\3LOOIRU3UHYHQWLRQRI&9'LQDQ8UEDQ,UDQLDQ3RSXODWLRQZLWK6SHFLDO)RFXVRQ1RQDOFRKROLF6WHDWRKHSDWLWLV 
Golestan Cohort Study
(50,045)
Aged 50 years & 
living in Gonbad 
(7,351)
Random selection of
2,400 participants: 
weighted to obtain a 
50:50 split (males:
females)
Random allocation to
PolyPill / Control in
110 / 90 ratio
PolyPill: invited by
telephone to participate
N = 1249 (94.6%) 
Agree to participate
after telephone call
N = 1,031 (78.1%)
Following one day run-
in period, no immediate
side-effects & return for 
tablets (787) (59.6%) 
Do not agree to
participate / failed to
contact
N = 218 (16.5%)
Meet eligibility criteria
and give consent
N = 875 (66.3%)
Do not meet eligibility
criteria or do not
consent
N = 156 (11.8%)
Immediate side-effects 
or do not return for 
tablets
N = 88 (6.7%)
Died or migrated
N = 71 (5.4%)
Randomised to PolyPill
N = 1320
Randomised to control 
N = 1080 
Control: invited by
telephone to participate
N = 1017 (94.2%) 
Died or migrated 
N = 63 (5.8%)
Do not agree to
participate / failed to
contact
N = 182 (17.2%)
Do not meet eligibility
criteria or do not
consent
N = 110 (10.2%)
Agreed to participate 
after telephone call
N = 831 (76.9%)
Meet eligibility criteria
and give consent
N = 721 (66.8%)
Followed up for primary
and cardiovascular 
outcomes
Followed up for liver related outcomes
Figure 1. &216257GLDJUDPRISDUWLFLSDQWÀRZWKURXJKWKHVWXG\ 
Table 2.3DUWLFLSDQWVORVWDIWHUUDQGRPL]DWLRQ. 
Total randomised 
Migrated 
Died 
Total remaining in Zelen trial (cardiovascular outcomes) 
Refused to participate 
Could not attend 
Could not be contacted by telephone 
Failed to attend baseline assessment 
Total attending baseline assessment for the additional measurements study (liver related outcomes) 
Intervention Control Total 
1320 1080 2400 
13 8 21 
58 55 113 
1249 1017 2266 
135 108 243 
55 60 115 
22 12 34 
6 6 12 
1031 831 1862 
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 60HUDW+3RXVWFKL.+HPPLQJHWDO 
Table 3.%DVHOLQHFKDUDFWHULVWLFVRISDUWLFLSDQWVLQFOXGHGLQWKH=HOHQWULDOFROOHFWHGGXULQJFRKRUWHQUROOPHQWDW±. 
PolyPill arm 
1  
Control arm 
1  
Male 608 (48.7%) 495 (48.7%) 
Age at 2011 years, mean (SD) 59.5 (7.5) 60.1 (7.6) 
Height cm, mean (SD) 160.6 (9.1) 160.8 (9.5) 
Weight kg, mean (SD) 73.2 (13.3) 73.0 (14.2) 
BMI kg/m2, mean (SD) 28.4 (5.1) 28.3 (5.3) 
Waist circumference cm, mean (SD) 99.9 (12.2) 99.6 (12.5) 
Hip circumference cm, mean (SD) 103.2 (9.0) 103.1 (9.6) 
Systolic blood pressure mmHg, mean (SD) 128.1 (23.0) 129.0 (23.6) 
Diastolic blood pressure mmHg, mean (SD) 78.1 (12.0) 78.6 (12.8) 
Smoking history, ever 264 (21.2%) 224 (22%) 
Diabetes mellitus 115 (9.2%) 96 (9.4%) 
Car ownership 443 (35.5%) 321 (31.6%) 
House ownership 1169 (93.6%) 953 (93.7%) 
Computer ownership 332 (26.6%) 259 (25.5%) 
9DOXHVDUHQXPEHUVDQGSHUFHQWDJHVXQOHVVRWKHUZLVHVSHFL¿HG 
Table 4. Baseline characteristics of participants included in the additional measurements study.* 
Polypill Control 
Variable N = 1031 N = 831 
Male (%) 50.3% 52.2% 
Age (years) 58.5 (6.5) 59.4 (7.0) 
Cardiovascular variables 
Height (cm) 161.6 (9.0) 161.8 (9.6) 
Weight (kg) 74.1 (13.2) 73.9 (14.0) 
Hip circumference (cm) 101.7 (8.3) 101.3 (9.0) 
Waist circumference (cm) 99.9 (12.3) 99.6 (12.4) 
Body Mass Index (kg/m2) 28.4 (4.9) 28.2 (5.0) 
Total Cholesterol (mg/dL) 218.5 (42.7) 206.9 (40.1) 
High Density Lipoprotein cholesterol (mg/dL) 59.9 (15.4) 58.0 (14.3) 
Low Density Lipoprotein cholesterol (mg/dL) 128.5 (34.4) 120.7 (32.9) 
Triglycerides (mg/dL) 152.4 (82.6) 143.7 (81.4) 
Systolic Blood Pressure (mmHg) 130.8 (22.9) 135.0 (21.4) 
Diastolic Blood Pressure (mmHg) 78.2 (10.3) 82.4 (10.9) 
Liver related variables 
Liver stiffness (KPa), n=1580 5.1 (3.5) 5.1 (3.6) 
Aspartate aminotransferase (IU/L) 21.1 (10.6) 21.9 (11.4) 
Alanine aminotransferase (IU/L) 22.2 (15.3) 25.2 (18.9) 
Alkaline phosphatase (IU/L) 260.5 (82.6) 251.7 (100.5) 
Gamma-glutamyltransferase (IU/L) 31.1 (32.5) 35.6 (45.6) 
pNAFLD (%), n=1614 39.6% 40.6% 
Increased alanine aminotransferase (%) 28.1% 35.3% 
pNASH (%), n=1614 18.4% 22.5% 
Haematological variables 
Haemoglobin (gr/dL) 13.6 (1.5) 12.7 (1.5) 
White blood count (1000/mm3) 6.4 (1.8) 6.3 (1.7) 
Platelets (1000/mm3) 255.4 (62.1) 240.5 (66.4) 
Renal related variables 
Creatinine (mg/dL) 1.2 (0.3) 1.1 (0.3) 
Estimated Glomerular Filtration Rate (ml/min) 66.7 (17.0) 73.5 (20.0) 
Urea (mg/dL) 30.0 (9.2) 29.4 (8.1) 
Glucose metabolism variables 
Fasting Blood Sugar (mg/dl) 112.1 (44.2) 109.7 (45.0) 
Insulin (mU/L) 12.1 (8.4) 10.7 (9.0) 
HOMA-IR, n=1822 3.5 (3.6) 2.9 (2.7) 
Glycosylated haemoglobin (mg/L), n=473** 7.4 (1.7) 6.6 (2.9) 
*Figures are means and Standard Deviations unless stated otherwise. HOMA-IR: homeostatic model assessment insulin resistance. **Performed only for 
subjects with fasting blood sugar > 110 mg/dL. 
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3RO\3LOOIRU3UHYHQWLRQRI&9'LQDQ8UEDQ,UDQLDQ3RSXODWLRQZLWK6SHFLDO)RFXVRQ1RQDOFRKROLF6WHDWRKHSDWLWLV 
Contraindication to PolyPill 
Anemia 
Moderate or severe asthma 
Renal failure 
Hypotension 
Physical disability 
Hepatitis B or C 
Other reasons 
Total 
*Percentages are from participants selected from Golestan cohort study (1320 for PolyPill group, 1080 for controls). Some participants had more than one 
contraindication. 
PolyPill arm 
1  
Control arm 
1  
15 1.1% 22 2.0% 
19 1.4% 9 0.8% 
8 0.6% 6 0.6% 
20 1.5% 9 0.8% 
49 3.7% 32 3.0% 
24 1.8% 27 2.5% 
25 1.9% 15 1.4% 
156 11.8% 110 10.2% 
Table 5.)UHTXHQF\RIFRQWUDLQGLFDWLRQVLQSDWLHQWVVHOHFWHGIRUWKH3RO\3LOODQGFRQWURODUPV. 
of randomized participants is included in an additional measure- 2. 
ments study to investigate the effects of the PolyPill on liver re­
3.lated outcomes.
Strengths	 4. 
By selecting participants from an existing cohort study, the study
makes use of existing arrangements for follow up and is therefore
DKLJKO\HI¿FLHQWWULDOGHVLJQ8VLQJWKHIROORZXSDUUDQJHPHQWRI 5. 
the cohort study should minimize losses to follow up. The primary
outcome and other cardiovascular outcomes are independently as­
sessed through the cohort study. 6. 
Limitations 
Allocation was not concealed because cases and controls were 7.
invited separately. Fewer randomized participants entered the ad­
ditional measurements study in the PolyPill group than the control
group (59.6% vs. 66.8%). This may affect the interpretation of
the effects of the PolyPill on liver related outcomes. The study is 8. 
DOVRRSHQODEHODQGWKLVPD\LQÀXHQFHWKHDVVHVVPHQWRIVHFRQG­
ary outcomes. On the other hand, the liver related outcomes are 9. 
measured objectively; therefore, there is less scope for measure­
ment bias. 10. 
The Zelen design study has fewer limitations. Including all
randomized participants in the Zelen design means that the low
numbers entering the additional measurements study will not in- 11. 
ÀXHQFHWKHYDOLGLW\RIWKHUHVXOWVZLWKUHVSHFWWRFDUGLRYDVFXODU 
endpoints. Nevertheless, the effects of the PolyPill may be at­
tenuated by the fact that 40.4% of randomized participants did 12. 
not receive the PolyPill. However, if the PolyPill is to be used
in primary care, physicians may make similar judgements about 13. 
which patients should receive treatment as is the case in our study.
But some randomized participants may have declined the PolyPill
because they did not agree to additional measurements and ideally 14. 
we would have offered all randomized participants a PolyPill. 
Baseline characteristics for randomly allocated participants in 15. 
the Zelen study were obtained from the date of their enrollment
into the Golestan Cohort Study, which was about 5 to 10 years
previous to allocation. This means that they cannot be used for 16. 
baseline adjustment. However, as distribution of these differences
LVFRQVLVWHQWZLWKFKDQFHLWDOORZVXVWRFRQ¿UPWKDWDOORFDWLRQ 
was random. 17. 
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